| アイテムタイプ |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2025-06-24 |
| タイトル |
|
|
タイトル |
A repeated cross-sectional analysis of SARS-CoV-2 seroprevalence in Manila, the Philippines after implementation of the national COVID-19 vaccination program |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
COVID‑19 |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Philippines |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
SARS‑CoV‑2 |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Vaccination |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Seroepidemiological study |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
Malijan, Greco Mark B.
Suzuki, Shuichi
Sayo, Ana Ria
Villanueva, Annavi Marie
Agrupis, Kristal An
Ortal-Cruz, Abigail
Salazar, Mary Ann
Evangelista, Jan Wendzl
Solante, Rontgene
Go, Grace Devota
Saludar, Naomi Ruth
Miranda, Dinarazad
Dimapilis, Alexis
Ariyoshi, Koya
Smith, Chris
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Background: SARS-CoV-2 seroepidemiological studies, which have been used to describe population-level immunity, are limited in the Philippines, despite the protracted course of the epidemic in the country. We follow-up on our previous work and aimed to estimate SARS-CoV-2 seroprevalence and infection rate among outpatient clinic attendees in Metro Manila, a year after the implementation of the national COVID-19 vaccination program. Methods: We conducted four repeated cross-sectional surveys at the outpatient department of San Lazaro Hospital between March 2022 and January 2023. We performed χ2 test and analysis of variance to assess the differences in characteristics across different data collection periods. Results: A total of 765 participants were enrolled, ranging from 170 to 200 per period. Participant demographic, socioeconomic, and medical history were comparable across all data collection periods. Between March and October 2022, the proportion of participants who received a vaccine or booster dose significantly increased, from 77.9% to 90%. Seroprevalence across all data collection periods was consistently high, ranging from 97.8% to 99.5%. However, the geometric mean concentration of antibodies was highest in the data collection period following the Omicron-dominant wave. Infection rates were comparably low (< 10%) across periods, except for a peak at 16.7% in September to October 2022, which followed the rise in reported cases in Metro Manila. Conclusion: Population-level seroprevalence among clinic attendees in Manila was consistently high a year after implementation of the national COVID-19 vaccination program, but analyses of antibody concentrations showed potential waning within a 3-month period. |
|
言語 |
en |
| 書誌情報 |
en : Tropical Medicine and Health
巻 53,
号 1,
p. art. no. 81,
発行日 2025-06-16
|
| 出版者 |
|
|
出版者 |
BioMed Central Ltd |
|
言語 |
en |
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
1349-4147 |
| DOI |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1186/s41182-025-00767-9 |
| 権利 |
|
|
権利情報 |
© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
|
言語 |
en |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 引用 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
Tropical Medicine and Health, 53(1), art. no. 81; 2025 |
|
言語 |
en |
TMH53_81.pdf (1.2 MB)
